150 related articles for article (PubMed ID: 37673635)
1. [Molecular mechanisms of pediatric intractable leukemia].
Takita J
Rinsho Ketsueki; 2023; 64(8):810-815. PubMed ID: 37673635
[TBL] [Abstract][Full Text] [Related]
2. Relapsed/Refractory T- Acute Lymphoblastic Leukemia - Current Options and Future Directions.
Jeha S
Indian J Pediatr; 2024 Feb; 91(2):168-175. PubMed ID: 37642889
[TBL] [Abstract][Full Text] [Related]
3. [Therapeutic strategies for childhood high-risk acute lymphoblastic leukemia].
Lu XT
Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 45(2):327-32. PubMed ID: 23591360
[TBL] [Abstract][Full Text] [Related]
4. [Recurrent SPI1 fusions in pediatric T-cell acute lymphoblastic leukemia: novel mutations with poor prognosis].
Seki M; Takita J
Rinsho Ketsueki; 2018; 59(4):439-447. PubMed ID: 29743405
[TBL] [Abstract][Full Text] [Related]
5. [Precision medicine and molecular target drugs in pediatric hematologic malignancies: acute lymphoblastic leukemia].
Takita J
Rinsho Ketsueki; 2020; 61(6):657-664. PubMed ID: 32624540
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in pediatric acute lymphoblastic and myeloid leukemia.
Ravindranath Y
Curr Opin Oncol; 2003 Jan; 15(1):23-35. PubMed ID: 12490758
[TBL] [Abstract][Full Text] [Related]
7. Recurrent SPI1 (PU.1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia.
Seki M; Kimura S; Isobe T; Yoshida K; Ueno H; Nakajima-Takagi Y; Wang C; Lin L; Kon A; Suzuki H; Shiozawa Y; Kataoka K; Fujii Y; Shiraishi Y; Chiba K; Tanaka H; Shimamura T; Masuda K; Kawamoto H; Ohki K; Kato M; Arakawa Y; Koh K; Hanada R; Moritake H; Akiyama M; Kobayashi R; Deguchi T; Hashii Y; Imamura T; Sato A; Kiyokawa N; Oka A; Hayashi Y; Takagi M; Manabe A; Ohara A; Horibe K; Sanada M; Iwama A; Mano H; Miyano S; Ogawa S; Takita J
Nat Genet; 2017 Aug; 49(8):1274-1281. PubMed ID: 28671687
[TBL] [Abstract][Full Text] [Related]
8. Investigational treatment options in phase I and phase II trials for relapsed or refractory acute lymphoblastic leukemia in pediatric patients.
Asare JM; Rabik CA; Muller B; Brown PA; Cooper S
Expert Opin Investig Drugs; 2021 Jun; 30(6):611-620. PubMed ID: 33896328
[No Abstract] [Full Text] [Related]
9. [Long-term outcome of childhood T-cell acute lymphoblastic leukemia treated with modified national protocol of childhood leukemia in China-acute lymphoblastic leukemia 2008].
Liao C; Shen DY; Xu XJ; Xu WQ; Zhang JY; Song H; Yang SL; Zhao FY; Shen HP; Tang YM
Zhonghua Er Ke Za Zhi; 2020 Sep; 58(9):758-763. PubMed ID: 32872717
[No Abstract] [Full Text] [Related]
10. Non-leukemic pediatric mixed phenotype acute leukemia/lymphoma: Genomic characterization and clinical outcome in a prospective trial for pediatric lymphoblastic lymphoma.
Martin-Guerrero I; Salaverria I; Burkhardt B; Chassagne-Clement C; Szczepanowski M; Bens S; Klapper W; Zimmermann M; Kabickova E; Bertrand Y; Reiter A; Siebert R; Oschlies I
Genes Chromosomes Cancer; 2019 Jun; 58(6):365-372. PubMed ID: 30578714
[TBL] [Abstract][Full Text] [Related]
11. hTERT promoter methylation and telomere length in childhood acute lymphoblastic leukemia: associations with immunophenotype and cytogenetic subgroup.
Borssén M; Cullman I; Norén-Nyström U; Sundström C; Porwit A; Forestier E; Roos G
Exp Hematol; 2011 Dec; 39(12):1144-51. PubMed ID: 21914494
[TBL] [Abstract][Full Text] [Related]
12. [The treatment development for T cell acute lymphoblastic leukemia in children, adolescents, and young adults].
Sato A
Rinsho Ketsueki; 2022; 63(9):1325-1334. PubMed ID: 36198559
[TBL] [Abstract][Full Text] [Related]
13. The genomic landscape of pediatric acute lymphoblastic leukemia and precision medicine opportunities.
Tran TH; Hunger SP
Semin Cancer Biol; 2022 Sep; 84():144-152. PubMed ID: 33197607
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia.
Schotte D; De Menezes RX; Akbari Moqadam F; Khankahdani LM; Lange-Turenhout E; Chen C; Pieters R; Den Boer ML
Haematologica; 2011 May; 96(5):703-11. PubMed ID: 21242186
[TBL] [Abstract][Full Text] [Related]
15. Polo-like Kinase 4: the Variation During Therapy and its Relation to Treatment Response and Prognostic Risk Stratification in Childhood Acute Lymphoblastic Leukemia Patients.
Xu J; Zhao L
J Pediatr Hematol Oncol; 2023 May; 45(4):189-194. PubMed ID: 35973104
[TBL] [Abstract][Full Text] [Related]
16. Agents for refractory/relapsed acute lymphocytic leukemia in adults.
Qian LR; Fu W; Shen JL
Eur Rev Med Pharmacol Sci; 2014; 18(17):2465-74. PubMed ID: 25268091
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomics of childhood acute lymphoblastic leukemia.
Brenner TL; Pui CH; Evan WE
Curr Opin Mol Ther; 2001 Dec; 3(6):567-78. PubMed ID: 11804271
[TBL] [Abstract][Full Text] [Related]
18. TNF-α SNP rs1800629 and risk of relapse in childhood acute lymphoblastic leukemia: relation to immunophenotype.
Franca R; Rebora P; Athanasakis E; Favretto D; Verzegnassi F; Basso G; Tommasini A; Valsecchi MG; Decorti G; Rabusin M
Pharmacogenomics; 2014 Apr; 15(5):619-27. PubMed ID: 24798719
[TBL] [Abstract][Full Text] [Related]
19. [Genetic basis of pediatric T-cell acute lymphoblastic leukemia and its clinical impact].
Takita J
Rinsho Ketsueki; 2018; 59(7):953-959. PubMed ID: 30078808
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetics in acute lymphoblastic leukemia.
Cheok MH; Pottier N; Kager L; Evans WE
Semin Hematol; 2009 Jan; 46(1):39-51. PubMed ID: 19100367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
